Invasive disease due to Neisseria meningitidis continues to cause debility and death worldwide in otherwise healthy individuals. Disease epidemiology varies globally, but most cases are due to serogroups A, B, C, W-135 or Y. MenactraTM (MCV-4), a quadrivalent, meningococcal diphtheria-conjugate vaccine against serogroups A, C, Y, and W-135, was licensed in the USA for individuals 11-55 years of age. Published results of clinical trials demonstrated robust immune responses that correlate with indicators of protection. MCV-4-induced antibody persist for up to 3 years after administration and anamnestic responses to revaccination. The vaccine was well tolerated; the most common reactions were transient, mild injection-site reactions and headache. MCV-4 should provide significant clinical benefits in the future.

Original publication

DOI

10.1586/14760584.5.4.445

Type

Journal article

Journal

Expert Rev Vaccines

Publication Date

08/2006

Volume

5

Pages

445 - 459

Keywords

Antibodies, Bacterial, Diphtheria Toxoid, Humans, Meningitis, Meningococcal Vaccines, Serotyping, Vaccines, Conjugate